Has Jed Kaminetsky, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,462,856 in general payments to Jed Kaminetsky, MD across 448 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jed Kaminetsky, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jed Kaminetsky, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jed Kaminetsky, MD

Urology · Middle Village, NYNPI 1952378598

Payments from drug & device makers

$3,462,856in general payments, 2019–2025

Across 448 payments — averaging $7729.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Vanda Pharmaceuticals Inc.$2.1M
AbbVie$476K
Endo Pharmaceuticals Inc.$426K
Siemens Medical Solutions USA, Inc.$81K
Janssen Research & Development, LLC$60K
Dendreon Pharmaceuticals LLC$42K
plus $243K from 41 others

$30,250in research payments, 2019–2025

Across 4 payments — averaging $7562.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Uroviu Corporation$24K
Dendreon Pharmaceuticals LLC$7K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Vanda Pharmaceuticals Inc.	66	$2,135,666
AbbVie(2 entities)	114	$475,511
Endo Pharmaceuticals Inc.	43	$425,609
Siemens Medical Solutions USA, Inc.	7	$80,984
Janssen Research & Development, LLC	5	$60,150
Dendreon Pharmaceuticals LLC	7	$42,157
Urovant Sciences Inc	9	$39,069
OPKO Pharmaceuticals, LLC	6	$38,557
Urogen Pharma, Inc.	11	$31,380
Sumitomo Pharma America, Inc.	15	$30,080
GSK	13	$23,938
Ferring Pharmaceuticals AS	1	$23,272
Olympus America Inc.	25	$13,417
Antares Pharma, Inc.	16	$9,642
Endo USA, Inc.	3	$7,312
Boston Scientific	9	$4,878
Clarus Therapeutics Inc.	5	$4,007
Acerus Pharmaceuticals Corporation	9	$3,427
AstraZeneca	3	$2,807
Laborie Medical Technologies Corp.	3	$2,769
Uroviu Corporation	2	$2,100
Olympus Corporation Of The Americas	5	$1,350
Spectrum Pharmaceuticals Inc.	1	$1,294
AMAG Pharmaceuticals, Inc.	3	$1,141
Progenics Pharmaceuticals, Inc.	6	$441
Johnson & Johnson	5	$327
Astellas Pharma US Inc	15	$302
Bioprotect Medical, Inc.	3	$175
Pfizer	7	$156
Tolmar, Inc.	2	$155
Blue Earth Diagnostics	1	$145
Immunitybio, Inc.	4	$123
Dentsply IH AB	3	$62
Novartis	2	$58
Halozyme Inc	2	$48
Merck	2	$48
Bayer	2	$42
Ferring Pharmaceuticals Inc.	1	$39
Verity Pharmaceuticals Inc.	2	$37
Civco Medical Instruments	1	$36
Aytu Biopharma, Inc.	2	$30
Myriad Genetic Laboratories, Inc.	2	$28
Dentsply IH Inc.	1	$25
Coloplast	1	$17
Neotract Inc.	1	$17
Azurity Pharmaceuticals, Inc.	1	$15
Metuchen Pharmaceuticals	1	$13

How this compares

$3,462,856 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024

$766,575

Medicare patients

981

Services billed

52,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Middle Village

Christopher PieczonkaSyracuse$31.2M
Guarionex DecastroNew York$5.7M
Mitchell EfrosGarden City$4.2M
James McKiernanNew York$4.1M
William HuangNew York$3.9M
Evan GoldfischerPoughkeepsie$3.1M
Gennady BratslavskySyracuse$2.5M
Ashutosh TewariNew York$2.5M
Manish ViraNew Hyde Park$2.1M
Peter WalterJamestown$1.9M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →